

November 04, 2025

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001
BSE Scrip Code: 524743

To

National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor
Plot No. C/ 1, G Block,
Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051
NSE Symbol: FISCHER

Dear Sir,

Reg : Press Release: Time Medical International Ventures (India) Pvt Ltd, a Wholly Owned Subsidiary of Fischer Medical Ventures Limited announces Development of Inter - Op MRI Under the Leadership of Dr. Iype Cherian

We enclose a press release regarding "**Time Medical International Ventures (India) Pvt Ltd, a wholly owned subsidiary of Fischer Medical Ventures Limited announces Development of Inter - Op MRI Under the Leadership of Dr. Iype Cherian**", for dissemination.

Thanking you,
Yours Truly,
For **FISCHER MEDICAL VENTURES LIMITED**
(Formerly known as Fischer Chemic Limited)



ARAVINDKUMAR V
COMPANY SECRETARY & COMPLIANCE OFFICER



CIN L86900AP1993PLC118162

Corporate Office : Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006
Registered Office : No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032

Time Medical International Ventures (India) Pvt Ltd, a wholly owned subsidiary of Fischer Medical Ventures Limited announces Development of Inter - Op MRI Under the Leadership of Dr. Iype Cherian


Time Medical International Ventures (I) P LTD, a wholly owned subsidiary of Fischer Medical Ventures Limited, today announced a strategic collaboration with globally acclaimed neurosurgeon Dr. Iype Cherian, a pioneering neurosurgeon, educator, and innovator of international repute to develop a revolutionary new variant of MRI technology — DRIS–iMRI Medharanya.

31st October 2025 – Chennai - Time Medical International Ventures (I) P LTD is a global leader in advanced medical imaging solutions and a wholly owned subsidiary of Fischer Medical Ventures Ltd. Headquartered in Chennai, Time Medical India specializes in the design and manufacture of high-performance, cost-effective MRI systems that democratize access to advanced diagnostic imaging across emerging and developed markets alike.

Through this collaboration, Time Medical and Dr. Cherian will jointly develop a revolutionary new variant of MRI technology — DRIS–iMRI Medharanya, an AI-enabled, next-generation, portable and specialized MRI system integrating augmented reality (AR), artificial intelligence (AI), machine learning (ML), and exoscope technologies.

The Interop MRI is designed to revolutionize interoperative imaging, providing surgeons with real-time visualization during complex neurosurgical procedures. This innovation enables unprecedented precision, safety, and control in surgeries that traditionally rely on limited visual feedback.

DRIS–iMRI Medharanya represents a next-generation, AI-enabled, portable MRI system that integrates Augmented Reality (AR), Artificial Intelligence and Machine Learning (AI/ML), and Exoscope technologies. Designed to transform neurosurgical and neurodiagnostic practice, it enables unparalleled precision, visualization, and accessibility in real-time interoperative imaging.



Clinically, DRIS–iMRI Medharanya also embodies the **Extradural Parasigmoid approach to the Jugular Foramen (Ex Pa JuF)** — a groundbreaking surgical pathway for managing complex **glomus tumours** with enhanced safety and anatomical clarity.



About Dr. Iype Cherian

Dr. Iype Cherian is a pioneering neurosurgeon, educator, and innovator whose distinguished career embodies surgical mastery, inventive spirit, and global impact. After completing his **M.Ch (Neurosurgery)** at CMC Vellore and a **Fellowship in Skull Base and Vascular Neurosurgery** at Nagoya, he has devoted his life to advancing neurosurgical science and education. His groundbreaking contributions include the description of Craniotomy (2007) and the concept of Brain Cooling, both of which have influenced contemporary neurosurgical practice and postoperative recovery strategies.



Renowned for “Unlocking the Skull Base,” he has developed advanced microsurgical routes such as the **Transcavernous** and **Modified Kawase** approaches, creating safer access to complex intracranial regions. His inventive portfolio — including the **Sanma Yoko Exoscope, STMC Bypass Set, Medharanya Theatre Concept, Sookshmaranga Endovascular Robot**, and now **DRIS-iMRI Medharanya** — reflects his mission to democratize precision surgery.

Currently serving as **Director of Neuro Sciences at the Nepal Institute of Medical Sciences & Research** and as faculty at the **Institute of NeuroSciences, Krishna Institute of Medical Sciences, Karad**, he continues to mentor surgeons worldwide through **Neurosurgery Coach**, his global training initiative promoting advanced micro-neurosurgical skill development.



Under this collaboration, Dr. Iype Cherian will assume the role of **Director – Neurosciences** at *Time Medical India*, where he will guide the clinical innovation, neuroimaging design, and translational strategy of the DRIS-iMRI Medharanya program. This partnership reflects Time Medical’s commitment to advancing imaging technology that bridges intelligence, accessibility, and human-centered design.



Quotes:

Dr. Iype Cherian, Neurosurgeon at Parul University, explained:

"Glioma surgery is generally a blind surgery. Interoperative MRI gives vision to the surgeon — allowing them to see what has been taken and what is left. Small interparenchymal lesions would be much easier to remove definitively if live imaging were available interoperatively."

Ms. Svetlana, Director, Time Medical International Ventures (I) P Ltd:

"With Dr. Cherian's expertise and vision, Time Medical is entering an exciting new phase of innovation. The Interop MRI represents our commitment to developing cutting-edge, accessible solutions that bring world-class imaging into the surgical environment."

For further information, please contact:

Fischer Medical Ventures Limited

Email: enquiry@fischermv.com

Website: www.fischermv.com

Contact: **9080966548**

Disclaimer:

This investor release is not an offer to sell any securities or a solicitation to buy any securities of Fischer Medical Ventures Limited (the "company") or its subsidiaries (together with the company, the "group"). Certain statements in this document may be forward looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "or" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intention. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements.

Forward looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved.

The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Investor Release, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. **FISCHERMVL** will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward- looking statements to reflect subsequent events or circumstances.
